What PE Investors Actually Want From Your Commercial Team

The question behind the question

When a PE investor asks about your commercial team, they are not asking whether you have good salespeople. They are asking whether you have a system that can be relied upon to produce a specific outcome at a specific cost — and whether that system holds up when you push it.

Most healthcare company leaders prepare for the first question. The second one is harder.

Predictability over performance

A strong quarter does not impress a sophisticated investor the way founders often expect. What impresses them is the ability to explain why the quarter went the way it did — and to demonstrate that the next one is already visible in the pipeline.

Investors buy future cash flows. They are making a bet on what the business will produce over the next three to five years, not on what it produced last quarter. The commercial team's job, from the investor's perspective, is to make that future legible and credible.

A company that can say, with confidence, that it closes thirty percent of qualified pipeline in an average of ninety days at an average contract value of X, and that pipeline is currently at Y, is a company with a predictable revenue engine. That is what investors are looking for. Not the biggest number. The most reliable one.

Scalability over size

The second question investors are asking is whether the commercial motion scales. A company with fifteen million in revenue needs to demonstrate that the system that got it there can plausibly get it to fifty.

Scale breaks commercial systems in predictable ways. Pricing discipline erodes when deal size increases and every contract becomes a negotiation. Marketing and sales misalign when the team gets large enough that they stop sitting in the same room. The ICP blurs when the company chases revenue in adjacent segments without updating its motion. Implementation falls behind sales.

Investors who have seen this cycle — and most have — look for evidence that the leadership team has thought about these inflection points before reaching them.

What the commercial team needs to show

There are three things that tend to move investor confidence most in a commercial diligence conversation.

First, a clean ICP. Who is the buyer, why do they buy, and what does a qualified opportunity look like. Companies that can answer this precisely — not with a broad category but with specific attributes — signal that they have done the work to understand their market.

Second, a conversion model. What enters the pipeline, what percentage advances at each stage, and what the exit rate is at the bottom. When the numbers are real and the team owns them, the conversation is different than when they are assembled for the meeting.

Third, a retention story. In healthcare, where implementation is hard and switching costs are real, the ability to retain and expand a customer base is as important as the ability to add new ones. Investors want to see that the company keeps what it wins.

The most common gap

The most common gap in PE-backed healthcare companies is not a talent gap. It is a senior ownership gap. The CEO is the de facto CRO, carrying the commercial strategy alongside everything else. The VP of Sales is strong inside the quarter. The architecture questions — whether the system scales, what the conversion model actually is, where the next growth curve comes from — have no dedicated owner.

That works until it does not. And it tends to stop working right when the investor's expectations are highest.

Getting ahead of that gap — before the board meeting where the numbers are wrong — is the work that matters most. Harborline Growth Advisory provides that senior ownership on a fractional basis, scoped to what the company needs and built to last beyond the engagement.

---

Related reading: The 90-Day Commercial Reset for Post-Acquisition Healthcare Companies